Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent
Arthritis, Psoriatic
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2
4 insiders sold shares within a month
Since Aug 17, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 453 (final count)
- Started
- Sep 28, 2021
- Main results expected
- Oct 28, 2024
- Fully finished
- Jul 2, 2026
- Results posted
- Dec 8, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24
Measured over: At Week 24
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2, since 2026-08-17, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04936308 · record last updated 2026-11-03 · checked 2026-11-09 15:47 UTC